+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immuno-Oncology Market by Therapy Type, Indication, End User, Line of Therapy, Mechanism - Global Forecast to 2030- Product Image
Immuno-Oncology Market by Therapy Type, Indication, End User, Line of Therapy, Mechanism - Global Forecast to 2030- Product Image
Sale

Immuno-Oncology Market by Therapy Type, Indication, End User, Line of Therapy, Mechanism - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5889363
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The immuno-oncology market is undergoing significant transformation as advances in immunotherapies reshape cancer care and open new frontiers for clinical and commercial innovation. This report provides senior decision-makers with a data-driven analysis of market opportunities, emerging challenges, and practical imperatives for sustained growth and leadership in a rapidly evolving landscape.

Market Snapshot: Immuno-Oncology Market Growth

The immuno-oncology market grew from USD 5.89 billion in 2024 to USD 6.51 billion in 2025. Demonstrating robust expansion at a CAGR of 10.03%, it is expected to reach USD 10.46 billion by 2030. This momentum is driven by scientific breakthroughs in checkpoint inhibitors, cell-based therapies, and regulatory shifts that foster innovation and accelerate access. The landscape encompasses a diverse array of therapy types, cancer indications, and end users, with the United States, Europe, Asia-Pacific, and key regional markets playing pivotal roles in driving clinical adoption and commercial success.

Scope & Segmentation: Defining the Market Landscape

This report delivers a comprehensive segmentation of the immuno-oncology market, analyzing all core areas:

  • Therapy Type: Cancer vaccines, cell therapies (CAR-T: both allogeneic and autologous; NK cell; TCR-T), checkpoint inhibitors (CTLA-4, PD-1, PD-L1), cytokines, and oncolytic viruses.
  • Indication: Breast cancer (including Her2-positive and triple-negative), colorectal cancer, lung cancer (non-small cell, small cell), lymphoma, and melanoma (cutaneous, uveal).
  • End User: Academic institutes, specialized research centers, clinics, and hospitals.
  • Line of Therapy: First line, second line, third line, and fourth line or beyond.
  • Mechanism: Active immunotherapies (cancer vaccines, cytokine-based therapies), passive approaches (adoptive cell transfer, checkpoint inhibitors, monoclonal antibodies).
  • Regional Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, and others), Asia-Pacific (China, India, Japan, Australia, and additional countries).
  • Leading Companies: Bristol-Myers Squibb, Merck & Co., Roche, AstraZeneca, Gilead Sciences, Novartis, Amgen, Pfizer, Eli Lilly, Johnson & Johnson.

This segmentation enables thorough examination of competitive landscape, adoption patterns, and technology trends across key regions and therapy categories.

Key Takeaways for Senior Decision-Makers

  • Checkpoint inhibitor innovation and combination regimens are rapidly expanding therapeutic options for both solid and hematologic cancers.
  • Cell therapy manufacturing is transitioning from autologous to scalable allogeneic models, supporting broader patient reach and operational efficiencies.
  • Regional investment in manufacturing and process development is rising in response to supply chain complexity and the need for tariff resilience.
  • Collaboration models—spanning biopharma, academic, and contract organizations—are pivotal for accelerating development, approval, and commercialization.
  • Strategic segmentation in end user and therapy lines enables targeted messaging, aligning product value with specialist needs and care settings.
  • Integration of digital analytics enhances trial management, post-market surveillance, and supports evidence-based reimbursement discussions.

Tariff Impact: U.S. 2025 Regulatory Environment

The 2025 United States tariff changes introduce new complexities across the immuno-oncology supply chain, particularly for biologic and cell therapy materials. Companies are responding with strategic sourcing shifts, prioritizing domestic partnerships and regional manufacturing hubs to mitigate supply disruption. These adjustments require scalable process development and robust inventory strategies to protect against clinical and commercial risks.

Methodology & Data Sources

Analysis is grounded in primary interviews with oncologists, regulatory specialists, and manufacturing leaders, complemented by thorough secondary research of scientific literature, financial disclosures, and regulatory filings. Data triangulation and scenario analysis strengthen segmentation accuracy, competitive benchmarking, and supply chain assessments within this report.

Why This Report Matters to Decision-Makers

  • Informs investment, R&D, and commercialization strategies by offering clear, segmented views of market drivers and adoption barriers.
  • Equips stakeholders with actionable intelligence to address regulatory, technological, and supply chain challenges in core and emerging markets.
  • Supports targeted go-to-market planning and risk mitigation by mapping end user priorities, therapy pathways, and regional trends.

Conclusion

Immuno-oncology presents compelling opportunities for transformative patient outcomes and long-term market growth. With informed strategies and resilient operations, leaders can navigate shifts in regulation, technology, and global trade to achieve commercial success.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Immuno-Oncology Market, by Therapy Type
8.1. Introduction
8.2. Cancer Vaccines
8.2.1. Cancer Vaccines
8.2.1.1. Dendritic Cell Vaccines
8.2.1.2. DNA Vaccines
8.2.1.3. Peptide Vaccines
8.3. Cell Therapy
8.3.1. CAR-T Therapy
8.3.1.1. Allogeneic
8.3.1.2. Autologous
8.3.2. NK Cell Therapy
8.3.3. TCR-T Therapy
8.4. Checkpoint Inhibitors
8.4.1. CTLA-4 Inhibitors
8.4.2. PD-1 Inhibitors
8.4.3. PD-L1 Inhibitors
8.5. Cytokines
8.6. Oncolytic Viruses
9. Immuno-Oncology Market, by Indication
9.1. Introduction
9.2. Breast Cancer
9.2.1. Her2-Positive Breast Cancer
9.2.2. Triple-Negative Breast Cancer
9.3. Colorectal Cancer
9.4. Lung Cancer
9.4.1. Nsclc
9.4.2. Small Cell Lung Cancer
9.5. Lymphoma
9.6. Melanoma
9.6.1. Cutaneous Melanoma
9.6.2. Uveal Melanoma
10. Immuno-Oncology Market, by End User
10.1. Introduction
10.2. Academic Institutes
10.3. Cancer Research Institutes
10.4. Clinics
10.5. Hospitals
11. Immuno-Oncology Market, by Line of Therapy
11.1. Introduction
11.2. First Line
11.3. Fourth Line Or Beyond
11.4. Second Line
11.5. Third Line
12. Immuno-Oncology Market, by Mechanism
12.1. Introduction
12.2. Active Immunotherapy
12.2.1. Cancer Vaccines
12.2.2. Cytokine-Based Therapy
12.3. Passive Immunotherapy
12.3.1. Adoptive Cell Transfer
12.3.1.1. CAR-T Therapy
12.3.1.2. TCR-T Therapy
12.3.2. Checkpoint Inhibitors
12.3.3. Monoclonal Antibodies
13. Americas Immuno-Oncology Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Immuno-Oncology Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Immuno-Oncology Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Bristol-Myers Squibb Company
16.3.2. Merck & Co., Inc.
16.3.3. Roche Holding AG
16.3.4. AstraZeneca PLC
16.3.5. Gilead Sciences, Inc.
16.3.6. Novartis AG
16.3.7. Amgen Inc.
16.3.8. Pfizer Inc.
16.3.9. Eli Lilly and Company
16.3.10. Johnson & Johnson
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. IMMUNO-ONCOLOGY MARKET MULTI-CURRENCY
FIGURE 2. IMMUNO-ONCOLOGY MARKET MULTI-LANGUAGE
FIGURE 3. IMMUNO-ONCOLOGY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2024 VS 2030 (%)
FIGURE 16. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. IMMUNO-ONCOLOGY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. IMMUNO-ONCOLOGY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. IMMUNO-ONCOLOGY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TCR-T THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ONCOLYTIC VIRUSES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY HER2-POSITIVE BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TRIPLE-NEGATIVE BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY NSCLC, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CUTANEOUS MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY UVEAL MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY FOURTH LINE OR BEYOND, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CYTOKINE-BASED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TCR-T THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 101. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 102. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 103. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 104. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 105. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 106. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 107. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 108. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 109. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 110. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 111. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 113. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 114. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 115. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 116. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2018-2030 (USD MILLION)
TABLE 117. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 118. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 119. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 120. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 121. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 122. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 123. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 124. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 125. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 126. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 127. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 129. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 130. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 131. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 132. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2018-2030 (USD MILLION)
TABLE 149. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 150. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 151. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 152. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 153. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 154. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 155. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 156. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 157. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 158. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 159. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 161. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 162. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 163. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 164. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2018-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 182. UNITED KINGDOM IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 184. UNITED KINGDOM IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 194. UNITED KINGDOM IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 196. UNITED KINGDOM IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2018-2030 (USD MILLION)
TABLE 198. GERMANY IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 199. GERMANY IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 200. GERMANY IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 201. GERMANY IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 202. GERMANY IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 203. GERMANY IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 204. GERMANY IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 205. GERMANY IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 206. GERMANY IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 207. GERMANY IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 208. GERMANY IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. GERMANY IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 210. GERMANY IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 211. GERMANY IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 212. GERMANY IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 213. GERMANY IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2018-2030 (USD MILLION)
TABLE 214. FRANCE IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 215. FRANCE IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 216. FRANCE IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 217. FRANCE IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 218. FRANCE IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 219. FRANCE IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 220. FRANCE IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 221. FRANCE IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 222. FRANCE IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 223. FRANCE IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 224. FRANCE IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. FRANCE IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 226. FRANCE IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 227. FRANCE IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 228. FRANCE IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 229. FRANCE IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 236. RUSSIA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 237. RUSSIA IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 238. RUSSIA IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 239. RUSSIA IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 240. RUSSIA IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. RUSSIA IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 242. RUSSIA IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 243. RUSSIA IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 244. RUSSIA IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 245. RUSSIA IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2018-2030 (USD MILLION)
TABLE 246. ITALY IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 247. ITALY IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 248. ITALY IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 249. ITALY IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 250. ITALY IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 251. ITALY IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 252. ITALY IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 253. ITALY IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 254. ITALY IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 255. ITALY IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 256. ITALY IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. ITALY IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 258. ITALY IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 259. ITALY IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 260. ITALY IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 261. ITALY IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2018-2030 (USD MILLION)
TABLE 262. SPAIN IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 263. SPAIN IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 264. SPAIN IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 265. SPAIN IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 266. SPAIN IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 267. SPAIN IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 268. SPAIN IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 269. SPAIN IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 270. SPAIN IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 271. SPAIN IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 272. SPAIN IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. SPAIN IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 274. SPAIN IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 275. SPAIN IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 276. SPAIN IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 277. SPAIN IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2018-2030 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2018-2030 (USD MILLION)
TABLE 294. SAUDI ARABIA IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 296. SAUDI ARABIA IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 298. SAUDI ARABIA IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 300. SAUDI ARABIA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 302. SAUDI ARABIA IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 304. SAUDI ARABIA IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 306. SAUDI ARABIA IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 308. SAUDI ARABIA IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2018-2030 (USD MILLION)
TABLE 310. SOUTH AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 312. SOUTH AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 314. SOUTH AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 316. SOUTH AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 318. SOUTH AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 320. SOUTH AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 322. SOUTH AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 323. SOUTH AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 324. SOUTH AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 325. SOUTH AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2018-2030 (USD MILLION)
TABLE 326. DENMARK IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 327. DENMARK IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 328. DENMARK IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 329. DENMARK IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 330. DENMARK IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 331. DENMARK IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 332. DENMARK IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 333. DENMARK IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD MILLION)
TABLE 334. DENMARK IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 335. DENMARK IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2030 (USD MILLION)
TABLE 336. DENMARK IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 337. DENMARK IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 338. DENMARK IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2018-2030 (USD MILLION)
TABLE 339. DENMARK IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 340. DENMARK IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 341. DENMARK IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2018-2030 (USD MILLION)
TABLE 342. NETHERLANDS IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 343. NETHERLANDS IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 344. NETHERLANDS IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2030 (USD MILLION)
TABLE 345. NETHERLANDS IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 346. NETHERLANDS IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2030 (USD MILLION)
TABLE 347. NETHERLANDS IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 348. NETHERLANDS IMMU

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Immuno-Oncology market report include:
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Roche Holding AG
  • AstraZeneca PLC
  • Gilead Sciences, Inc.
  • Novartis AG
  • Amgen Inc.
  • Pfizer Inc.
  • Eli Lilly and Company
  • Johnson & Johnson

Table Information

Report AttributeDetails
No. of Pages196
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 6.51 Billion
Forecasted Market Value ( USD ) by 2030 $ 10.46 Billion
Compound Annual Growth Rate10.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Immuno-oncology Clinical Trials Market by Therapy Type, Trial Phase, Indication, Sponsor Type, Trial Type, Patient Enrollment - Global Forecast to 2030 - Product Image

Immuno-oncology Clinical Trials Market by Therapy Type, Trial Phase, Indication, Sponsor Type, Trial Type, Patient Enrollment - Global Forecast to 2030

  • Report
  • 189 Pages
  • Global
From
Precision Immuno-Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Precision Immuno-Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Immuno-Oncology - Global Strategic Business Report - Product Image

Immuno-Oncology - Global Strategic Business Report

  • Report
  • 224 Pages
  • Global
From
Immuno-Oncology Drugs Market Report 2025 - Product Image

Immuno-Oncology Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Immuno Oncology Assays Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Immuno Oncology Assays Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 185 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.